DEBBANE RAYMOND 4

What Happened
Raymond Debbane, a director of Lexicon Pharmaceuticals (LXRX), reported two open-market purchases (code P) totaling 150,000 shares. On Feb 19, 2026 he acquired 50,000 shares at a weighted average price of $1.44 for $71,965 (prices ranged $1.425–$1.455). On Feb 20, 2026 he acquired 100,000 shares at a weighted average price of $1.48 for $147,790 (prices ranged $1.47–$1.49). Total reported outlay was approximately $219,755. These were purchases (acquisitions), which investors often view as more informative than routine sales.

Key Details

• Transaction dates: Feb 19, 2026 (50,000 shares) and Feb 20, 2026 (100,000 shares).
• Reported prices and totals: 50,000 @ $1.44 = $71,965; 100,000 @ $1.48 = $147,790; total ≈ $219,755.
• Footnotes: F1 and F2 indicate the reported prices are weighted averages; actual trades ranged $1.425–$1.455 (F1) and $1.47–$1.49 (F2). The filer will provide trade-by-trade details on request.
• Shares owned after the transactions: not specified in the provided filing details.
• Filing info: Form 4 filed Feb 23, 2026 (covers transactions on Feb 19–20); this filing date appears consistent with the typical two-business-day Form 4 deadline. Accession: 0001062822-26-000031.

Context
Debbane is listed as a company director (not indicated as a 10% owner or an executive in the provided data). No options exercises, awards, gifts, or tax-withholding transactions are reported in this filing—these were straightforward open-market purchases. Purchases by insiders can be meaningful to retail investors but do not prove future performance; this summary is factual and does not speculate on intent.